Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Azeliragon (TTP488) 是一种生物可利用的、可穿过血脑屏障 (BBB)的晚期糖基化终产物 (RAGE) 受体抑制剂,可缓解轻度阿尔茨海默病 (AD) 的发展。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 387 | 现货 | ||
2 mg | ¥ 559 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,270 | 现货 | ||
25 mg | ¥ 2,520 | 现货 | ||
50 mg | ¥ 3,830 | 现货 | ||
100 mg | ¥ 5,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 972 | 现货 |
产品描述 | Azeliragon (TTP488) is an antagonist at the Receptor for Advanced Glycation End products; is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer_acute_s disease (AD). |
激酶实验 | Recombinant Kinase Assays [1]: The ability of AZD5438 to inhibit cdk activity is examined using a scintillation proximity assay with recombinant cdk-cyclin complexes of cyclin-Ecdk2, cdk2-cyclin A, cdk4-cyclin D, and recombinant retinoblastoma substrate (amino acids 792-928) or cdk1-cyclin B1 with a peptide substrate derived from the in vitro p34cdc2 phosphorylation site of histone H1 (biotin-X-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu). The activity of AZD5438 against recombinant cdk5/p25 (at 2 μM ATP) is determined in a scintillation proximity assay-based assay using peptide substrate (AKKPKTPKKAKKLOH). Inhibition of glycogen synthase kinase 3β activity is determined with scintillation proximity assay based on the use of human purified glycogen synthase kinase 3βenzyme and eukaryotic initiation factor 2B substrate (at 1 μM ATP). AZD5438 is screened against active recombinant human cdk6-cyclin D3, cdk7-cyclin H/MAT1 (cdk activating kinase complex), and cdk9-cyclin T using the kinase selectivity screening service. |
别名 | TTP488, 阿齐瑞格 |
分子量 | 532.12 |
分子式 | C32H38ClN3O2 |
CAS No. | 603148-36-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (20.67 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8793 mL | 9.3964 mL | 18.7928 mL | 46.9819 mL |
5 mM | 0.3759 mL | 1.8793 mL | 3.7586 mL | 9.3964 mL | |
10 mM | 0.1879 mL | 0.9396 mL | 1.8793 mL | 4.6982 mL | |
20 mM | 0.094 mL | 0.4698 mL | 0.9396 mL | 2.3491 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Azeliragon 603148-36-3 Neuroscience Others Beta Amyloid advanced glycation end products Abeta PF 04494700 TTP 488 Amyloid-β inhibit PF04494700 PF-04494700 TTP-488 TTP488 β-amyloid peptide Inhibitor 阿齐瑞格 inhibitor